LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 631 participants.
Also called NCT01380730
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 631 participants
- Sponsor
- Registry
-
NCT01380730
-
- Other papers using this trial's data
- AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Denmark, Hungary
- Registry status
- Completed
Technical summary
Registry record NCT01380730. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-01 (actual); primary completion 2012-04-05 (actual). Results posted on 2015-10-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
- Acronym
- LAPLACE
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Other)
- Placebo to Evolocumab
- Lead sponsor
- Amgen
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct01380730- Content hash
93215bcbe9af51b40ccc4e3fe5a56a4499216032f770d2e5fe3d55982f85b92d